Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syndax PharmaceuticalsFRA:1T3 +2.52%20 Cyclically Adjusted PS Ratio is 24.57 as of Jul. 31, 2026, which is 14% below its 10-year median of 28.62. GuruFocus rates FRA:1T3 with a GF Score™ of 20/100. The stock has 7 warning signs investors should review. Among 538 Biotechnology companies, Syndax Pharmaceuticals ranks worse than 85.13% on this metric.
The historical rank and industry rank for Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
FRA:1T3'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 16.36 Med: 28.62 Max: 52.11
Current: 24.06
During the past years, Syndax Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 52.11. The lowest was 16.36. And the median was 28.62.
FRA:1T3's Cyclically Adjusted PS Ratio is ranked worse than 85.13% of 538
companies
in the Biotechnology industry
Industry Median: 5.53
vs FRA:1T3: 24.06
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Syndax Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2026 was €0.636. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.68 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Syndax Pharmaceuticals (FRA:1T3) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Syndax Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms
Syndax Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syndax Pharmaceuticals Cyclically Adjusted PS Ratio Chart
FRA:1T3 vs FTRE, KARD, STOK: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syndax Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Syndax Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Syndax Pharmaceuticals Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 24.57 mean?
Syndax Pharmaceuticals (FRA:1T3) has a Cyclically Adjusted PS Ratio of 24.57 as of Jul. 31, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Syndax Pharmaceuticals and its competitors. This is 14% below median its historical median of 28.62. Over the past decade, Syndax Pharmaceuticals' Cyclically Adjusted PS Ratio has ranged from 16.36 to 52.11. According to the industry distribution chart, Syndax Pharmaceuticals ranks #458 out of 538 companies in the Biotechnology industry, placing it in the top 85.1%.
Is Syndax Pharmaceuticals' Cyclically Adjusted PS Ratio too high?
Syndax Pharmaceuticals' current Cyclically Adjusted PS Ratio of 24.57 is 14% below median its 10-year median of 28.62. Over the past 10 years, this metric has ranged from a low of 16.36 to a high of 52.11. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.53. Syndax Pharmaceuticals' value of 24.57 is 344.3% above this industry median. Based on the distribution chart, Syndax Pharmaceuticals ranks #458 out of 538 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syndax Pharmaceuticals has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Cyclically Adjusted PS Ratio compare to FTRE and KARD?
According to the Biotechnology industry distribution chart, Syndax Pharmaceuticals ranks #458 out of 538 companies for Cyclically Adjusted PS Ratio. This places Syndax Pharmaceuticals in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.53. Syndax Pharmaceuticals' value of 24.57 is 344.3% above this benchmark. Historically, Syndax Pharmaceuticals' own Cyclically Adjusted PS Ratio has ranged from 16.36 to 52.11 over the past decade. While the company's 10-year median is 28.62 vs. the industry median of 5.53, Syndax Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.53, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syndax Pharmaceuticals's current Cyclically Adjusted PS Ratio of 24.57 is 344.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Syndax Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syndax Pharmaceuticals's current Cyclically Adjusted PS Ratio is 24.57, which is 14% below median its own 10-year median of 28.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Cyclically Adjusted PS Ratio of 24.57. The current Cyclically Adjusted PS Ratio is 24.57, which is 14% below median its 10-year median of 28.62 and 344.3% above the Biotechnology industry median of 5.53. Syndax Pharmaceuticals' overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Cyclically Adjusted PS Ratio is 24.57 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
20GF Score
Get the complete analysis for FRA:1T3
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1T3 has been successfully added to your 
